IP Library Granted Patent US 12,215,142
Granted Patent B2
US 12,215,142 · App. 16/980,667 · Granted Feb 4, 2025

Antibody fragment degrading and removing abnormal TDP-43

Inventors: Makoto Urushitani (Otsu, JP); Yoshitaka Tamaki (Otsu, JP)
Assignee: NATIONAL UNIVERSITY CORPORATION SHIGA UNIVERSITY OF MEDICAL SCIENCE
C07K16/18A61P25/28A61K2039/505A61K48/00C07K2317/24C07K2317/565C07K2317/567C07K2317/622C07K2317/76C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,215,142
App. No.
16/980,667
Granted
Feb 4, 2025
Kind
B2
Abstract

A modified antibody fragment comprising an antibody fragment capable of binding to misfolded TDP-43, and a chaperone-mediated autophagy localizing signal peptide.

Claims (11)

1. A modified antibody fragment that binds to misfolded TAR DNA-binding protein of 43 kDa, wherein the modified antibody fragment comprises an antibody fragment and a chaperone-mediated autophagy localizing signal peptide comprising KFREQ (SEQ ID NO: 8) and linked to the C-terminus of the antibody fragment;

the antibody fragment comprising:

a heavy-chain variable region comprising a heavy-chain CDR 1 consisting of an amino acid sequence GFNIKDYY (SEQ ID NO: 1), a heavy-chain CDR 2 consisting of an amino acid sequence IDPEDGET (SEQ ID NO: 2), and a heavy-chain CDR 3 consisting of an amino acid sequence TIIYYYGSRYVDY (SEQ ID NO: 3); and

a light-chain variable region comprising a light-chain CDR 1 consisting of an amino acid sequence SSISSSY (SEQ ID NO: 4), a light-chain CDR 2 consisting of an amino acid sequence RTS, and a light-chain CDR 3 consisting of an amino acid sequence QQGSSIPLT (SEQ ID NO: 5); and

wherein the antibody fragment is a scFv; and

wherein the antibody fragment and the chaperone-mediated autophagy localizing signal peptide are directly bonded, or an amino acid sequence exists between them.

2. The modified antibody fragment according to claim 1 , wherein the antibody fragment is a humanized antibody fragment.

3. A nucleic acid encoding the modified antibody fragment according to claim 1 .

4. An expression vector comprising the nucleic acid according to claim 3 .

5. A method of inducing a heat shock protein in a cell, the method comprising administering the nucleic acid according to claim 3 .

6. The method of claim 5 , wherein the heat-shock protein is Hsp70.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2020
From: URUSHITANI, MAKOTO; TAMAKI, YOSHITAKA
To: NATIONAL UNIVERSITY CORPORATION SHIGA UNIVERSITY OF MEDICAL SCIENCE
Reel/Frame 053762/0550 →
Priority Claims (1)
JP 2018-049752 · Mar 16, 2018 · national
Continuity (1)
Related Publication 20210024621A1 · Jan 28, 2021
References Cited (31)
US 9334331B2 · Igawa · 2016 [cited by examiner]
US 10421807B2 · Gonzales · 2019 [cited by examiner]
US 20110287453A1 · Hasegawa et al. · 2011 [cited by applicant]
US 20180305464A1 · Li et al. · 2018 [cited by applicant]
US 20200010570A1 · Li et al. · 2020 [cited by applicant]
CN 107151269A · 2017 [cited by applicant]
JP 2013162772A · 2013 [cited by applicant]
JP 2014171425A · 2014 [cited by applicant]
WO 2009008529A1 · 2009 [cited by applicant]
WO 2013061163A2 · 2013 [cited by applicant]
Tamaki (Nature (2018) 8:6030 |; pp. 1-16 ). [cited by examiner]
Al Qaraghuli et al. (2020, Nature Scientific Reports 10:13969). [cited by examiner]
Edwards et al. (2003, JMB 334:103-118). [cited by examiner]
Lloyd et al. (2009, Protein Engineering, Eng. Design & Selection 22(3): 159-168). [cited by examiner]
Goel et al. (2004, J. Immunol. 173: 7358-7367). [cited by examiner]
Khan et al. (2014, J. Immunol. 192: 5398-5405). [cited by examiner]
Poosarla et al. (2017, Biotechn. Bioeng. 114(6): 1331-1342). [cited by examiner]
Heale et al (Alzheimer's and Dementia, (Jul. 2018) vol. 14, No. 7, Supp. Supplement, pp. P1294-P1295. Meeting Info: Alzheimer's Association International Conference 2018. Chicago, IL, United States. Jul. 22-Jul. 26, 201… [cited by examiner]
Office Action dated Oct. 28, 2022 for corresponding Chinese Patent Application No. 201980027565.X, 8 pages. [cited by applicant]
International Search Report (with English translation) mailed Jun. 4, 2019 for corresponding International Application No. PCT/JP2019/010771, 5 pages. [cited by applicant]
Tamaki et al., “Degradative intrabody for selective elimination of pathogenic TDP-43 aggregates in vitro and in murine embryos' cerebrum”, Journal of Neurological Sciences, 2017, vol. 381, p. 715, Abstract No. 1984. [cited by applicant]
Tamaki et al., “Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific Intrabody with dual proteolytic signals”, Scientic Reports, Apr. 16, 2018, vol. 8, Article No. 6030, 16 p… [cited by applicant]
Urushitani et al., “Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis”, Proceedings of the National Academy of Sciences, Feb. 13, 2007, vol. 104, No. 7,… [cited by applicant]
Shodai et al., “Aberrant Assembly of RNA Recognition Motif 1 Links to Pathogenic Conversion of TAR DNA-binding Protein of 43 kDa (TDP-43)”, the Journal of Biological Chemistry, May 24, 2013, vol. 288, No. 21, pp. 14886-… [cited by applicant]
Tamaki et al., “The development of therapeutic intrabody against misfolded/mislocalized TDP-43 for ALS”, Clinical Neurology, 2016, vol. 56, S370, Pe-045-6, 1 page. [cited by applicant]
Extended European Search Report dated Nov. 16, 2021 for corresponding European Patent Application No. 19768492.1, 13 pages. [cited by applicant]
Christian Münz, “Antigen processing via autophagy—not only for MHC class II presentation anymore?”, Current Opinion in Immunology, 2010, vol. 22, No. 1, pp. 89-93. [cited by applicant]
Makoto Urushitani, “The role of TDP-43 in ALS pathogenesis”, Neurological Therapeutics, 2017, vol. 34, No. 2, pp. 72-78 with English abstract. [cited by applicant]
Khalid et al., “Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials”, Frontiers in Neurology, 2017, vol. 8, Article 486, 11 pages. [cited by applicant]
Uchida et al., “CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes In ALS”, Scientific Reports, 2016, vol. 6, 19118, 19 pages. [cited by applicant]
Pozzi et al., “Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology”, The Journal of Clinical Investigation, 2019, vol. 129, No. 4, pp. 1581-1595. [cited by applicant]